首页> 外文期刊>Saudi Journal of Biological Sciences >Nimbolide ameliorates the streptozotocin-induced diabetic retinopathy in rats through the inhibition of TLR4/NF-κB signaling pathway
【24h】

Nimbolide ameliorates the streptozotocin-induced diabetic retinopathy in rats through the inhibition of TLR4/NF-κB signaling pathway

机译:Nimbolide通过抑制TLR4 / NF-κB信号通路来改善大鼠链脲佐菌素诱导的糖尿病视网膜病变

获取原文
           

摘要

Background Diabetic retinopathy (DR) is a common problem in the diabetic patients due to the high blood glucose level. DR affects more number of diabetic patients worldwide with irreversible vision loss. Objective The current investigation was focused to reveal the therapeutic actions of nimbolide against the streptozotocin (STZ)-provoked DR in rats through inhibition of TLR4/NF-κB pathway. Methodology DR was provoked to the rats through administering a single dose of STZ (60?mg/kg) intraperitoneally. The DR rats were then supplemented with the 50?mg/kg of nimbolide for 60?days. The bodyweight and blood glucose level was measured using standard methods. The lipid profiles (cholesterol, TG, LDL, and HDL), inflammatory markers, and antioxidants level was detected using respective kits. The level of MCP-1, VEGF, and MMP-9 was quantified using kits. The morphometric analysis of retinal tissues were done. The mRNA expressions of target genes were studied using RT-PCR assay. Results Nimbolide treatment effective decreased the food intake and blood glucose, and improved the bodyweight of STZ-provoked animals. The levels of pro-inflammatory mediators, cholesterol, TG, LDL, and HDL, MCP-1, VEGF, and MMP-9 was remarkably suppressed by the nimbolide treatment. Nimbolide also improved the antioxidants, retinal thickness and cell numbers. The TLR4/NF-κB pathway was appreciably inhibited by the nimbolide. Conclusion Overall, our findings demonstrated that the nimbolide attenuated the STZ-provoked DR in rats through inhibiting the TLR4/NF-κB pathway.
机译:背景技术糖尿病视网膜病变(DR)是糖尿病患者的常见问题,由于高血糖水平。 DR影响全世界更多糖尿病患者,具有不可逆的视力丧失。目的目前的调查集中于通过TLR4 / NF-κB途径抑制揭示杜米蛋白对大鼠链脲佐菌素(STZ)ovo过量的博士的治疗作用。通过腹膜内施用单剂量的STZ(60×mg / kg)来激发对大鼠的方法。然后将RAT大鼠补充有50μg/ kg弯曲奈德60?天。使用标准方法测量体重和血糖水平。使用各自的试剂盒检测脂质谱(胆固醇,Tg,LDL和HDL),炎症标记和抗氧化剂水平。使用试剂盒量化MCP-1,VEGF和MMP-9的水平。完成了视网膜组织的形态学分析。使用RT-PCR测定研究了靶基因的mRNA表达。结果奈博德治疗有效降低了食物摄入量和血糖,改善了STZ激发动物的体重。通过弯耳治疗显着抑制了促炎介质,胆固醇,Tg,LDL和HDL,MCP-1,VEGF和MMP-9的水平。奈博德还改善了抗氧化剂,视网膜厚度和细胞数。弯曲粘膜明显抑制TLR4 / NF-κB途径。结论总体而言,我们的研究结果表明,拐蝶形纤维化蛋白通过抑制TLR4 / NF-κB途径通过抑制大鼠的STZ激发博士。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号